Project description
A cancer-on-chip platform for drug discovery
Three-dimensional cell cultures are emerging as promising models for cancer drug discovery, toxicology as well as preclinical and personalised medicine studies. Apart from their biomimetic nature and reproducibility of results, they also facilitate the reduction of animal experimentation. The EU-funded MImETIC INDiRECT project has developed a microfluidics-based culture system that encompasses a chip chamber coated with an extracellular matrix as well as temperature and oxygen sensors. Importantly, the system uses optimised growth factor culture media and is compatible with imaging equipment. Researchers will employ cell lines to reconstruct in vitro 3D cancer models and promote these versatile cell-on-chip platforms for commercialisation.
Objective
MImETIC INDiRECT aims to develop a standardised, accessible, versatile organ-on-chip toolkit for cancer biology and drug discovery research, compatible with microscopy-based (live imaging and confocal) techniques. The project is expected to facilitate academia and industry adoption of microfluidic 3D cell culture systems for comparable and reproducible results in a complex biomimetic animal free model for cancer drug discovery, toxicology, advanced (pre)clinical as well as personalized medicine. The toolkit components will consist of an integrated temperature controller dual-chamber chip, the Cherry Biotech CubiX system and growth factor optimized collagenous solutions for each chip chamber. The dual chamber chip, with cellular migration lanes, will have two tailored collagen-based formulations, designed per chamber. The CubiX platform is a compact flow and temperature controller, allowing optional sensor (e.g. O2) integration, compatible with single chips or 24-well plates. The cancer(s) sub-types to be used toolkit standardization will be dictated by market needs, where commercial cell lines (cancerous and non-cancerous) will be used to create the microvascularized complex tissue model. Potential project risks have been identified with appropriate mitigation strategies, where the project promotes adoption of standardized, cost-effective and versatile cancer organ-on-chip platforms in the market, rather than disruptive academic findings. Access of the aforementioned system to a worldwide growth market will fully exploit the project results, disseminated by direct and indirect marketing and scientific approaches. Project implementation will be an academic-industry collaborative and multidisciplinary manner providing the acquisition of diverse and unconventional complementary skills, leading to an understanding of both sectors requirements. We envision the above-mentioned to facilitate future academic and industry collaborations.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- engineering and technology electrical engineering, electronic engineering, information engineering electronic engineering sensors
- medical and health sciences clinical medicine oncology
- medical and health sciences health sciences personalized medicine
- engineering and technology other engineering and technologies microtechnology organ on a chip
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-SE - Society and Enterprise panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2018
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
93100 MONTREUIL
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.